The adverse effects and use of bevacizumab in patients with glioblastoma: a systematic review and meta-analysis

Vista sencilla de ítem
dc.contributor.authorBruna-Mejías, Alejandro
dc.contributor.authorSilva-Bravo, Vicente
dc.contributor.authorMoyano Valarezo, Laura
dc.contributor.authorDelgado-Retamal, María Fernanda
dc.contributor.authorNazar-Izquierdo, Diego
dc.contributor.authorAguilar-Aguirre, Isidora
dc.contributor.authorNova-Baeza, Pablo
dc.contributor.authorOrellana-Donoso, Mathias
dc.contributor.authorSuazo Santibañez, Alejandra
dc.contributor.authorGutiérrez-Espinoza, Héctor
dc.contributor.authorSanchis Gimeno, Juan
dc.contributor.authorBastidas-Caldes, Carlos
dc.contributor.authorValenzuela Fuenzalida, Juan José
dc.date.accessioned2025-09-29T13:32:10Z
dc.date.available2025-09-29T13:32:10Z
dc.date.issued2025-05-25
dc.description.abstractA glioblastoma (GBM) is a type of tumor originating from the glial brain cells, the astrocytes, and thus belongs to the astrocytoma group. Bevacizumab (BV) is a treatment for GBM. BV is the active ingredient in the drugs Avastin®, Alymsys®, Mvasi® and ZiraBev®. It is currently approved as second-line treatment for GBM recurrence in combination with radiotherapy, and as first-line treatment for other cancers, including advanced colorectal cancer, metastatic breast cancer and advanced non-small-cell lung cancer. The objective of this systematic review was to analyze the scientific evidence from the science-based literature on the therapeutic effect and adverse effects of the drug BV in patients with GBM or GBM multiforme. Methods: We systematically searched electronic databases for the literature search, including the MEDLINE (via PubMed), SCOPUS, Google Scholar, the Cumulative Index to Nursing and Allied Health Literature and Web of Science databases, covering records from their earliest data to December 2024. Randomized or controlled clinical trials that were published in English or Spanish were included. The following keywords were used in different combinations: “Bevacizumab therapy”, “Bevacizumab pharmaceutical”, “Glioblastoma”, “Glioma” and “multiform glioblastoma”. Results: The use of Bevacizumab has been extensively studied in the scientific literature, with beneficial effects in symptom control. However, the adverse effects of BV vary across different types of carcinomas, which is why it has already been established that these adverse effects must be taken into consideration. In our meta-analysis of adverse effects, we found 14 adverse effects and estimated their prevalence, with an average of 19% (CI: 4 to 44%). The most significant vascular adverse effect was thromboembolism, which led to a greater number of complications for patients with GBM. Finally, the most common adverse effects were nausea, vomiting, fatigue and hypertension. Conclusions: While the beneficial properties of this pharmacological therapy have been observed, its adverse effect profile requires constant evaluation, as it includes vascular, blood and symptomatic adverse effects, which must be analyzed on a case-by-case basis and with great attention, especially in the case of more serious complications such as thromboembolic events.
dc.identifier.citationPharmaceuticals, Vol. 18, N°6, 795 (2025) p. 1-36.
dc.identifier.doihttps://doi.org/10.3390/ph18060795
dc.identifier.issn1424-8247
dc.identifier.orcidhttps://orcid.org/0000-0002-1781-062X
dc.identifier.urihttps://hdl.handle.net/20.500.12254/4318
dc.language.isoen
dc.publisherMDPI
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectBevacizumab therapy
dc.subjectBevacizumab pharmaceutical
dc.subjectGlioblastoma
dc.subjectMultiform glioblastoma
dc.subjectGlioma
dc.titleThe adverse effects and use of bevacizumab in patients with glioblastoma: a systematic review and meta-analysis
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Paper5-The Adverse Effects.pdf
Tamaño:
8.38 MB
Formato:
Adobe Portable Document Format
Descripción:
Texto completo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas